ライフサイエンスコーパス: rheumatoid

1 ns, such as systemic lupus erythematosus and rheumatoid arthritis

2 t predictors (hazard ratios) of failure were rheumatoid arthritis (2.36), late post-surgical infectio

3 The most common cause of secondary SS was rheumatoid arthritis (98.1%), followed by systemic lupus

4 .8; 95% confidence interval [CI] = 1.2-2.5), rheumatoid arthritis (adjusted OR = 1.7; 95% CI = 1.5-1.

5 59, 95% CI: 0.39-0.87), or specifically with Rheumatoid Arthritis (aHR=0.64), Granulomatosis with Pol

6 of TNF-alpha and IL-17A in a mouse model of rheumatoid arthritis (collagen-induced arthritis) and th

7 ary or secondary panuveitis (HR = 4.21), and rheumatoid arthritis (HR = 3.30) were significantly asso

8 1), inflammatory bowel disease (n = 27,739), rheumatoid arthritis (n = 25,324), systemic lupus erythe

9 ondylitis (OR = 0.72; 95% CI, 0.54-0.98) and rheumatoid arthritis (OR = 0.65; 95% CI, 0.50-0.84).

10 hinese, OR = 2.35 in European Americans) and rheumatoid arthritis (OR = 1.65 in Koreans).

11 era were derived from four large cohorts: 1) rheumatoid arthritis (RA) (n = 194, HD n = 64), 2) type

12 in the pathogenesis of systemic inflammatory rheumatoid arthritis (RA) and AD.

13 ible correlation of periodontal disease with rheumatoid arthritis (RA) and ankylosing spondylitis (AS

14 ds are frequently used for the management of rheumatoid arthritis (RA) and other chronic conditions,

15 e used extensively in clinical management of rheumatoid arthritis (RA) and other chronic inflammatory

16 umerous biologic agents for the treatment of rheumatoid arthritis (RA) and other forms of inflammator

17 s, including inflammatory arthritis, such as rheumatoid arthritis (RA) and psoriatic arthritis, perio

18 une-mediated inflammatory diseases including rheumatoid arthritis (RA) and spondyloarthritis (SpA).

19 the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematos

20 ications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematos

21 cells are implicated in the pathogenesis of rheumatoid arthritis (RA) and TNF-alpha, a proinflammato

22 Patients with rheumatoid arthritis (RA) are at high risk of developing

23 Patients with rheumatoid arthritis (RA) are at increased risk for infe

24 ulatory mechanisms of drug-free remission in rheumatoid arthritis (RA) are unknown.

25 rthritis (LA), using osteoarthritis (OA) and rheumatoid arthritis (RA) as comparators.

26 The progressive debilitating nature of rheumatoid arthritis (RA) combined with its unknown etio

27 luster of differentiation 4 (CD4) T cells in rheumatoid arthritis (RA) develop remains poorly underst

28 Current treatments for rheumatoid arthritis (RA) do not reverse underlying aber

29 Monocytes in the context of rheumatoid arthritis (RA) exhibit increased CPP uptake a

30 g mRNAs and long non-coding RNA (lncRNAs) in rheumatoid arthritis (RA) fibroblast-like synoviocytes (

31 ed gene expression signatures to distinguish rheumatoid arthritis (RA) from non-inflammatory arthralg

32 ng (MRI) to guide treatment in patients with rheumatoid arthritis (RA) improves disease activity and

33 Pathogenic T cells in individuals with rheumatoid arthritis (RA) infiltrate non-lymphoid tissue

34 Rheumatoid arthritis (RA) is a chronic autoimmune diseas

35 Rheumatoid arthritis (RA) is a chronic autoimmune disord

36 Rheumatoid arthritis (RA) is a chronic immune-mediated d

37 Rheumatoid arthritis (RA) is a chronic inflammatory auto

38 Rheumatoid arthritis (RA) is a chronic inflammatory auto

39 Rheumatoid arthritis (RA) is a chronic inflammatory dise

40 Rheumatoid Arthritis (RA) is a chronic inflammatory diso

41 Rheumatoid arthritis (RA) is a common systemic inflammat

42 Rheumatoid arthritis (RA) is a debilitating and painful

43 Rheumatoid arthritis (RA) is an autoimmune disease chara

44 Rheumatoid arthritis (RA) is an inflammatory autoimmune

45 Rheumatoid arthritis (RA) is an inflammatory joint disea

46 The primary manifestation of rheumatoid arthritis (RA) is articular disease; however,

47 Rheumatoid arthritis (RA) is characterised by painful, s

48 Rheumatoid arthritis (RA) is closely associated with sha

49 Although joint pain in rheumatoid arthritis (RA) is conventionally thought to r

50 the increased risk of heart failure (HF) in rheumatoid arthritis (RA) is independent of ischemic hea

51 Rheumatoid arthritis (RA) is the most common immune-medi

52 l of recombinant human TRAIL in experimental rheumatoid arthritis (RA) models.

53 sent a considerable burden for patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA).

54 rs in healthy donors (HDs) and patients with rheumatoid arthritis (RA) or systemic lupus erythematosu

55 ave an important role in the pathogenesis of rheumatoid arthritis (RA) owing to their ability to gene

56 on-invasive imaging of arthritis activity in rheumatoid arthritis (RA) patients using macrophage PET

57 This study sought to determine whether rheumatoid arthritis (RA) patients without active synovi

58 e of myocardial microvascular dysfunction in rheumatoid arthritis (RA) patients without clinical card

59 nt component C4d in pooled synovial fluid of rheumatoid arthritis (RA) patients.

60 status of this pathway in various stages of rheumatoid arthritis (RA) progression is unknown.

61 Many patients with rheumatoid arthritis (RA) report symptom relief from cer

62 Rheumatoid arthritis (RA) risk has a large genetic compo

63 The immunopathogenesis of rheumatoid arthritis (RA) spans decades, beginning with

64 Third, integration with rheumatoid arthritis (RA) summary statistics from Europe

65 Large meta-analyses of rheumatoid arthritis (RA) susceptibility in European (EU

66 tes (FLS), one of the main cell types of the rheumatoid arthritis (RA) synovium, possess phenotypic a

67 MK, 60 healthy controls and 35 patients with rheumatoid arthritis (RA) were included.

68 Rheumatoid arthritis (RA), a chronic inflammatory diseas

69 Rheumatoid arthritis (RA), a common autoimmune disease,

70 ree decades of advances in the management of rheumatoid arthritis (RA), a substantial minority of pat

71 Rheumatoid arthritis (RA), an autoimmune disease, has re

72 are the two most prevalent autoantibodies in rheumatoid arthritis (RA), and are thought to have disti

73 in actively inflamed joints of patients with rheumatoid arthritis (RA), and most animal models for RA

74 ohn's disease (CD), multiple sclerosis (MS), rheumatoid arthritis (RA), and others are increasingly r

75 Systemic diseases such as diabetes, rheumatoid arthritis (RA), and systemic lupus erythemato

76 In rheumatoid arthritis (RA), breakdown of self-tolerance a

77 diagnosis is critical to improve outcomes in rheumatoid arthritis (RA), but current diagnostic tools

78 code a "shared epitope" (SE) associated with rheumatoid arthritis (RA), especially more severe cyclic

79 inated-peptide autoantibody) to diagnosis of rheumatoid arthritis (RA), including therapy-induced rem

80 ch as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), is increasingly recognised.

81 enosynovitis in the hands is associated with rheumatoid arthritis (RA), it is unknown whether tenosyn

82 diseases associated with osteolysis, such as rheumatoid arthritis (RA), often leading to disability i

83 fferentiate patients with FM from those with rheumatoid arthritis (RA), osteoarthritis (OA), or syste

84 In rheumatoid arthritis (RA), pathogenic T cells shift gluc

85 s specific for different forms of arthritis (rheumatoid arthritis (RA), psoriatic arthritis (PsA), os

86 kine in the inflamed joints of patients with rheumatoid arthritis (RA), together with compelling data

87 populations that drive joint inflammation in rheumatoid arthritis (RA), we applied single-cell RNA se

88 also been implicated in the pathogenesis of rheumatoid arthritis (RA), we evaluated the role of PON1

89 ng and deeply phenotyped patients with early rheumatoid arthritis (RA), we observe that peripheral bl

90 sted in a patient-derived in-vitro assay for Rheumatoid arthritis (RA), which yielded 5 promising gen

91 hat anti-neutrophil extracellular trap (NET) rheumatoid arthritis (RA)-rmAbs derived from CD19(+) B c

92 atus may indicate immunological remission in rheumatoid arthritis (RA).

93 ronmental risk factor for the development of rheumatoid arthritis (RA).

94 are postulated to be central in seropositive rheumatoid arthritis (RA).

95 damaged cells serves as a key autoantigen in rheumatoid arthritis (RA).

96 rovide the strongest genetic contribution to rheumatoid arthritis (RA).

97 s and miR-155 are increased in patients with rheumatoid arthritis (RA).

98 that has a long-recognized association with rheumatoid arthritis (RA).

99 well-known extra-articular manifestation of rheumatoid arthritis (RA).

100 ng pathways causing synovial inflammation in rheumatoid arthritis (RA).

101 etermine the osteoclastogenic role of H4R in rheumatoid arthritis (RA).

102 nercept-methotrexate in patients with active rheumatoid arthritis (RA).

103 is a proinflammatory cytokine implicated in rheumatoid arthritis (RA).

104 py ameliorates disease in many patients with rheumatoid arthritis (RA).

105 thesised to affect type 1 diabetes (T1D) and rheumatoid arthritis (RA).

106 nflammatory drug primarily used for treating rheumatoid arthritis (RA).

107 play a critical role in the pathogenesis of rheumatoid arthritis (RA).

108 ltiomics data for classification accuracy of rheumatoid arthritis (RA).

109 M AAbs) present in the sera of patients with rheumatoid arthritis (RA).

110 e development of autoimmune diseases such as rheumatoid arthritis (RA).

111 ding chronic inflammatory conditions such as rheumatoid arthritis (RA); however, it has only been dur

112 cupation of farming has been associated with rheumatoid arthritis (RA); pesticides may account for th

113 ients with multiple sclerosis (MS, n = 147), rheumatoid arthritis (RA, n = 229), Crohn's disease (n =

114 control subjects (n = 76) and patients with rheumatoid arthritis (RA, n = 244).

115 ce ratio [SIR]8.14), scleroderma (SIR 7.00), rheumatoid arthritis (SIR5.96), stillbirth (SIR4.50), an

116 Rheumatoid arthritis affects individuals commonly during

117 disorders (VTE risk is 4.7% in patients with rheumatoid arthritis and 2.5% in those without), and inh

118 old has been used for decades to treat human rheumatoid arthritis and benefits from 70-y hindsight on

119 key mediator in autoimmune diseases such as rheumatoid arthritis and Crohn's disease.

120 view, we assess this evidence in relation to rheumatoid arthritis and depression, with a focus on inn

121 vity was detected in the synovial fluid from rheumatoid arthritis and gout patients.

122 reatment for human autoimmune disorders like rheumatoid arthritis and inflammatory bowel disease yet

123 ental in many inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

124 ed 16S rRNA samples for periodontal disease, rheumatoid arthritis and inflammatory bowel diseases, as

125 cal treatment of autoimmune diseases such as rheumatoid arthritis and lupus.

126 is pathway, is a target for the treatment of rheumatoid arthritis and multiple sclerosis and is re-em

127 reported in few diseases/conditions such as rheumatoid arthritis and oral cancer, there are no repor

128 nflammatory disorders of the bone, including rheumatoid arthritis and osteoarthritis.

129 o protect from pathological bone loss during rheumatoid arthritis and osteoporosis, whose pathogenesi

130 improved clinical outcomes for patients with rheumatoid arthritis and other chronic autoimmune diseas

131 cal tumor necrosis factor (TNF) responses in rheumatoid arthritis and other inflammatory diseases.

132 GWAS results correlated with the genetics of rheumatoid arthritis and psoriasis.

133 sly identified as the primary risk factor in rheumatoid arthritis and referred to as the "shared epit

134 prove diagnosis of depression in people with rheumatoid arthritis and shed light on mechanisms that c

135 ng for the use of belimumab in patients with rheumatoid arthritis and Sjogren's syndrome.

136 ons for, inflammatory arthritides, including rheumatoid arthritis and spondyloarthritis.

137 ses, including systemic lupus erythematosus, rheumatoid arthritis and systemic sclerosis.

138 of various diseases such as atherosclerosis, rheumatoid arthritis and type 2 diabetes mellitus.

139 inhibitor (CAI) agents for the management of rheumatoid arthritis are reported.

140 Using rheumatoid arthritis as an example of T cell mediated di

141 being treated with natalizumab, and one with rheumatoid arthritis being treated with rituximab.

142 n can ameliorate autoimmune diseases such as rheumatoid arthritis by modulation of the immune system.

143 XCI-skew is increased in twins with Rheumatoid Arthritis compared to unaffected identical co

144 The RACAT (Rheumatoid Arthritis Comparison of Active Therapies) tri

145 e, synovial samples from human patients with rheumatoid arthritis contained CX(3)CR1(+)HLA-DR(hi)CD11

146 Genetics of rheumatoid arthritis contributes to biology and drug dis

147 pes were constructed for 213 AS cases and 46 rheumatoid arthritis controls using family data.

148 Patients with active rheumatoid arthritis despite stable methotrexate were ra

149 ly correlated with both clinical measures of rheumatoid arthritis disease activity and with synovial

150 ase-specific autoantibodies in patients with rheumatoid arthritis display a shift toward the pro-infl

151 vestigate the in vivo efficacy of auranofin (rheumatoid arthritis FDA-approved drug) in a CDI mouse m

152 channel expressed at the plasma membrane of rheumatoid arthritis fibroblast-like synoviocytes (RA-FL

153 nse to lipopolysaccharide challenge in human rheumatoid arthritis fibroblast-like synoviocytes.

154 anscriptional profiles 1 to 2 weeks before a rheumatoid arthritis flare.

155 Longitudinal genomic analysis of rheumatoid arthritis flares revealed PRIME cells in the

156 ntally healthy, and did not have diabetes or rheumatoid arthritis in 2000.

157 ess the efficacy and safety of sirukumab for rheumatoid arthritis in a phase 3 study (SIRROUND-T).

158 mumab plus methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequ

159 (RRs) and 95% confidence intervals (CIs) for rheumatoid arthritis in relation to different measures o

160 Rheumatoid arthritis is a chronic autoimmune disease tha

161 Rheumatoid arthritis is a chronic autoimmune disorder re

162 Strikingly, progression to rheumatoid arthritis is associated with altered expressi

163 Rheumatoid arthritis is characterized by progressive joi

164 y, FcRn blockade decreased inflammation in a rheumatoid arthritis model without reducing circulating

165 th autoimmune diseases other than SLE (e.g., rheumatoid arthritis or multiple sclerosis) or in sera f

166 ging evidence of the impact of infections on rheumatoid arthritis pathogenesis and flares.

167 Rheumatoid arthritis patients (n = 20) received single d

168 els of transmission in colorectal cancer and rheumatoid arthritis patients and, more generally, for s

169 ronounced in the primary synovial cells from rheumatoid arthritis patients than those from healthy do

170 disease-modifying antirheumatic drugs-naive rheumatoid arthritis patients was used to determine the

171 n synovial fibroblast-like synoviocytes from rheumatoid arthritis patients.

172 ynamics of iscalimab in healthy subjects and rheumatoid arthritis patients.

173 Case 1: A 52-year-old Thai female with rheumatoid arthritis presented with scleritis.

174 ll costimulation modulator, in patients with rheumatoid arthritis refractory to biologic disease-modi

175 In patients with rheumatoid arthritis refractory to biologic DMARDs, upad

176 circumference were associated with increased rheumatoid arthritis risk, suggesting adiposity could be

177 re similar to those in previous upadacitinib rheumatoid arthritis studies.

178 the sublining undergoes a major expansion in rheumatoid arthritis that is linked to disease activity(

179 In rheumatoid arthritis the synovial tissue undergoes marke

180 tion) has a principal role in progression of rheumatoid arthritis through generation of autoantibodie

181 ed home collection of blood in patients with rheumatoid arthritis to allow for longitudinal RNA seque

182 trepton, constituting a potential target for rheumatoid arthritis treatment.

183 The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to asse

184 d from the joints of patients suffering from rheumatoid arthritis underwent a GM-CSF-independent necr

185 on between all NNAI disorders and psychosis; rheumatoid arthritis was examined separately given the w

186 In addition, a patient with early rheumatoid arthritis was studied with both (68)Ga-DOTA-S

187 metatarsophalangeal joints was specific for rheumatoid arthritis when compared with findings in pati

188 irheumatic drugs (csDMARDs) in patients with rheumatoid arthritis who had an inadequate response to D

189 A 54-year-old white woman with a history of rheumatoid arthritis who was taking glucocorticoids and

190 INTERPRETATION: In patients with active rheumatoid arthritis who were refractory or intolerant t

191 ccessful treatment of multiple sclerosis and rheumatoid arthritis with anti-CD20 monoclonal antibodie

192 ute to chronic inflammatory diseases such as rheumatoid arthritis(1).

193 ry disease (hypothyroidism, hyperthyroidism, rheumatoid arthritis) associated with radiotherapy.

194 Inclusion criteria were (i) patients with rheumatoid arthritis, (ii) adult population age >/=16yea

195 cluding hypothyroidism, hyperthyroidism, and rheumatoid arthritis, also type-2 diabetes and osteoarth

196 ardiovascular disease, 3 each on obesity and rheumatoid arthritis, and 2 on chronic kidney disease.

197 dical history included basal cell carcinoma, rheumatoid arthritis, and Barrett esophagus.

198 onset and progression of multiple sclerosis, rheumatoid arthritis, and breast cancer.

199 act of AMDs on systemic lupus erythematosus, rheumatoid arthritis, and devastating monogenic disorder

200 (IC)-associated diseases, including SLE and rheumatoid arthritis, and following IgG Fcgamma receptor

201 ch as autoimmune disorders (type 1 diabetes, rheumatoid arthritis, and multiple sclerosis) and cardio

202 36 family members are involved in psoriasis, rheumatoid arthritis, and pulmonary diseases.

203 immunodeficiency virus infection, psoriasis, rheumatoid arthritis, and systemic lupus erythematosus p

204 mune diseases, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus.

205 in inflammatory diseases such as psoriasis, rheumatoid arthritis, and ulcerative colitis and neurolo

206 the tracer in larger group of patients with rheumatoid arthritis, as is planned for the next phase o

207 h characterization of the synovial tissue in rheumatoid arthritis, as well as psoriatic arthritis and

208 This disease network portraits rheumatoid arthritis, asthma, atherosclerosis, pulmonary

209 et inflammatory processes are used to manage rheumatoid arthritis, but have not translated well into

210 a previous familial linkage study of SLE and rheumatoid arthritis, but the association has not been e

211 In rheumatoid arthritis, C5orf30 expression is cell-specifi

212 diabetes, Crohn disease, ulcerative colitis, rheumatoid arthritis, celiac disease, psoriasis, and mul

213 isorders, such as atopic dermatitis, asthma, rheumatoid arthritis, colitis, and conjunctivitis, among

214 clinical applications including oncology and rheumatoid arthritis, could also be exploited in future

215 associated with numerous conditions such as rheumatoid arthritis, diabetes, systemic lupus erythemat

216 en overweight/obesity and risk of developing rheumatoid arthritis, however, the evidence is not entir

217 e and inflammatory-related diseases, such as rheumatoid arthritis, IgA nephropathy, ankylosing spondy

218 filgotinib, and baricitinib in patients with rheumatoid arthritis, inflammatory bowel diseases, psori

219 variety of physiological conditions such as rheumatoid arthritis, ischemia/reperfusion injury, strok

220 ches for various rheumatic diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, adu

221 Rheumatoid arthritis, like many inflammatory diseases, i

222 d in various pathological conditions such as rheumatoid arthritis, liver fibrosis, or obesity.

223 27,161 persons under 65 years of age who had rheumatoid arthritis, multiple sclerosis, hepatitis C, p

224 Aberrant PAD activity is associated with rheumatoid arthritis, multiple sclerosis, lupus, and cer

225 In active rheumatoid arthritis, NOTCH3 and Notch target genes are

226 r controls), individuals diagnosed with IBD, rheumatoid arthritis, or psoriasis after anti-TNFalpha i

227 ears) with inflammatory bowel disease (IBD), rheumatoid arthritis, or psoriasis and a primary cancer

228 ls from patients with acute Crohn's disease, rheumatoid arthritis, or sepsis were susceptible to both

229 wn to be effective in managing patients with rheumatoid arthritis, patient outcomes sensitive to nurs

230 chronic conditions such as atherosclerosis, rheumatoid arthritis, psoriasis, and Crohn's disease.

231 the treatment of chronic diseases, including rheumatoid arthritis, psoriasis, chronic pain, and hepat

232 The JAK inhibitor baricitinib, used to treat rheumatoid arthritis, reduces inflammation by modifying

233 es in PSs for coronary artery disease (CAD), rheumatoid arthritis, schizophrenia, waist-hip ratio (WH

234 losing spondylitis, polymyositis, psoriasis, rheumatoid arthritis, sicca syndrome, and systemic lupus

235 is of three types of inflammatory arthritis: rheumatoid arthritis, spondyloarthritis and systemic juv

236 of patients with rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, syst

237 In rheumatoid arthritis, the target of the immune response

238 ed in many human diseases, such as fibrosis, rheumatoid arthritis, tumor angiogenesis, and metastasis

239 ons in humans, including multiple sclerosis, rheumatoid arthritis, type-I diabetes, and cancer.

240 With a focus on rheumatoid arthritis, we sought new insight into genetic

241 collagen-induced arthritis, a mouse model of rheumatoid arthritis, which is associated with normalisa

242 volvement of Foxo3 in osteoclastogenesis and rheumatoid arthritis, which prompted us to further inves

243 Lung complications are a major cause of rheumatoid arthritis-related mortality.

244 y arthritis, including spondyloarthritis and rheumatoid arthritis.

245 anagement of psoriasis, Crohn's disease, and rheumatoid arthritis.

246 mune diseases such as multiple sclerosis and rheumatoid arthritis.

247 s of cohort studies on adiposity and risk of rheumatoid arthritis.

248 atory rheumatic disease of the elderly after rheumatoid arthritis.

249 associations with polymyalgia rheumatica and rheumatoid arthritis.

250 thma, atherosclerosis, neuropathic pain, and rheumatoid arthritis.

251 ces to improve autoimmune conditions such as rheumatoid arthritis.

252 it as a potential therapeutic candidate for rheumatoid arthritis.

253 of autoimmune diseases such as psoriasis and rheumatoid arthritis.

254 fment genes ELMO1, DOCK2, and RAC1 linked to rheumatoid arthritis.

255 on as a central event in the pathogenesis of rheumatoid arthritis.

256 alent BTK inhibitor being evaluated to treat rheumatoid arthritis.

257 rious chronic inflammatory diseases, such as rheumatoid arthritis.

258 rities to those targeted in the treatment of rheumatoid arthritis.

259 vation of B cells derived from patients with rheumatoid arthritis.

260 une conditions primary biliary cirrhosis and rheumatoid arthritis.

261 ted with several autoimmune diseases such as rheumatoid arthritis.

262 o enhanced inflammatory responses and severe rheumatoid arthritis.

263 h their pain-relieving effect, in a model of rheumatoid arthritis.

264 eumatism (EULAR) classification criteria for rheumatoid arthritis.

265 with leukocyte composition in blood and with rheumatoid arthritis.

266 a variety of autoimmune diseases, including rheumatoid arthritis.

267 )CD4(+) T cells in synovium of patients with rheumatoid arthritis.

268 T cell dysregulation as a central problem in rheumatoid arthritis.

269 of these IgGs can be used as biomarkers for rheumatoid arthritis.

270 is associated with the inflammatory state of rheumatoid arthritis.

271 rders such as inflammatory bowel disease and rheumatoid arthritis.

272 or (uPAR) in joint tissue from patients with rheumatoid arthritis.

273 raits, such as the interleukin-27 pathway in rheumatoid arthritis.

274 f PRIME cells in 19 additional patients with rheumatoid arthritis.

275 and safety of upadacitinib in patients with rheumatoid arthritis.

276 fficacy and safety profiles, particularly in rheumatoid arthritis.

277 and is the recommended first-line agent for rheumatoid arthritis.

278 losing spondylitis, and seronegative erosive rheumatoid arthritis.

279 most commonly inflammatory bowel disease and rheumatoid arthritis.

280 d a fundamentally different immunobiology to rheumatoid arthritis.

281 uggesting that VR23 can be selective against rheumatoid arthritis.

282 al selective Janus kinase inhibitor to treat rheumatoid arthritis.

283 tor infliximab in ankylosing spondylitis and rheumatoid arthritis; however, concerns about such indic

284 PRIME, cells in the blood from patients with rheumatoid arthritis; these cells shared features of inf

285 d address the concerns of people living with rheumatoid arthritis?

286 were suppressed in macrophages isolated from rheumatoid-arthritis patients, revealing a disease-assoc

287 mutations are linked with Progressive Pseudo Rheumatoid Dysplasia (PPRD) a debilitating musculoskelet

288 Rheumatoid factor (RF) and anti-citrullinated protein an

289 Urinalysis and rheumatoid factor (RF) tests were conducted to evaluate

290 mphoid malignancy in the formation of public rheumatoid factor autoantibodies responsible for mixed c

291 rs with sequelae showed significantly higher rheumatoid factor levels.

292 adjustment for CVD risk factors, joint pain, rheumatoid factor positivity, and inflammatory markers (

293 n non-B cells, we transferred anti-self-IgG (rheumatoid factor) B cells and their physiologic target

294 C-reactive protein, rheumatoid factor, antinuclear antibody, cytoplasmic ant

295 nti-cyclic citrullinated peptide antibodies, rheumatoid factor, complement levels, and cytokine level

296 n southern Europe (1360 [56.7%] of 2400) and rheumatoid factor-negative polyarthritis was more freque

297 hyroperoxidase antibody, and 37 positive for rheumatoid factor.

298 nts, anti-citrullinated protein antibody and rheumatoid factor.

299 Rheumatoid factors (RFs)-IgM and -IgA were measured by E

300 TNF-alpha, a proinflammatory cytokine in the rheumatoid joint, facilitates Th17 differentiation.